Aradigm Corporation

Aradigm is engaged in the development of novel pulmonary drug delivery systems designed to enhance the delivery and effectiveness of a number of existing development-stage drugs and reduce the need for injectable drug delivery. Aradigm's principal product development programs are based on its AERx(TM) Pulmonary Drug Delivery System, which uses proprietary technologies to create aerosols from liquid drug formulations for delivery locally to the lung or systemically via the lung. The Company believes that its systems can potentially be used to deliver a number of existing drugs for a variety ofapplications and may also offer a promising means of delivery for many new drugs being developed by pharmaceutical and biotechnology companies.

Contact Details: 3929 Point Eden Way Hayward CA 94545 United States of America Tel: 510 265 9000 Fax: 510 265 0277 Email: WWW: www.aradigm.com/

Loading...

Recent Publications by Aradigm Corporation:
The effects of system parameters on in vivo injection performance of a needle-free injector in human volunteers. PURPOSE: For a novel needle-free injection (NFI) system, the relationship...	5th September, 2007	Aradigm Corporation, Hayward, California, USA.	Pharm Res. 2007 Aug;24(8):1501-7. Epub 2007 Mar 23. DOI Direct Link
Pulmonary delivery of opioids as pain therapeutics. Pulmonary opioid delivery, on the basis of the fact that small molecular...	18th January, 2007	Aradigm Corporation,	Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1076-88. Epub 2006 Aug 12. DOI Direct Link
Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. The purpose of this study was to characterize performance of a...	6th May, 2005	Aradigm Corporation,	J Aerosol Med. 2005 Spring;18(1):34-44. DOI Direct Link
Effect of gender and device mouthpiece shape on bolus insulin aerosol delivery using the AERx pulmonary delivery system. PURPOSE: A study was designed to compare differences in insulin aerosol...	2nd March, 2005	Aradigm Corporation,	Pharm Res. 2004 Oct;21(10):1776-82.
Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. OBJECTIVE: The safety and pharmacokinetics of inhaled morphine in...	13th November, 2004	Aradigm Corporation,	Int J Clin Pharmacol Ther. 2004 Aug;42(8):456-62.
→View more Aradigm Corporation research publications.

Press Releases on Aradigm Corporation:
Reportlinker Adds Pulmonary Drug Delivery Technologies - A Global Market Perspective	18th November, 2009	Reportlinker	NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Pulmonary Drug Delivery Technologies - A Global Market Perspective http:/
Reportlinker Adds Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015	13th October, 2009	Reportlinker	NEW YORK, Oct. 13 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Insulin Delivery Devices Pipeline Technology and Market
Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer	2nd June, 2009	Bionovo, Inc.	EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) announced today the appointment of Klaus Kohl, Ph.D., as Senior Vice President and Chief Technical Officer. Dr. Kohl
Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D	2nd March, 2009	Alexza Pharmaceuticals, Inc.	MOUNTAIN VIEW, Calif., March 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Peter D. Noymer, PhD has been promoted to Vice President, Product Research

BioNews Results for Aradigm Corporation:
Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends	Freshnews.com:  Nov 10 2009 4:54PM Matching: aradigm
Aradigm Announces Third Quarter 2009 Financial Results	SmartBrief:  Nov 6 2009 7:06AM Matching: aradigm
GreenArrowStock.com: Green Zone Watch at GreenArrowStock.com: Aradigm Corporation (ARDM).	Individual.com:  Nov 5 2009 11:56PM Matching: aradigm
Aradigm Announces Third Quarter 2009 Financial Results	Therapeutics Daily:  Nov 5 2009 1:22PM Matching: aradigm
Aradigm Announces Third Quarter 2009 Financial Results	Genetic Engineering News:  Nov 5 2009 1:36PM Matching: aradigm
Promote your company here: BioNewsCast - Press Release Distribution	→View more Aradigm Corporation news.

Aradigm Corporation Clinical Trials:
Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis

Aradigm Corporation Patents:
US Patent No.	Title
6119953	Liquid atomization process
6369354	Excimer laser ablation process control of multilaminate materials
6408854	Insulin delivery enhanced by coached breathing
6427681	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
6428769	Acute testosterone administration
→View more Aradigm Corporation patents.

Aradigm Corporation (ARDM) Financial information Links from Barchart
ARDM Quote from from Barchart.com
ARDM Chart from from Barchart.com
ARDM Profile from from Barchart.com
ARDM Opinion from from Barchart.com
→View more Aradigm Corporation finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 310 times since April 2007, the link to the organisation's website has been followed 74 times

Search for more companies in Hayward

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Aradigm Corporation